OIC Clinical Trial
Official title:
A Phase 2b Randomized, Double-blind, Placebo-controlled, 12-week Study to Evaluate the Safety and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation
The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01702194 -
TD-1211 IV/Oral Mass Balance Study
|
Phase 1 | |
Withdrawn |
NCT04930237 -
RELISTOR's Effects on Opioid-Induced Constipation
|